Sumitomo Pharma (4506) financial statements

+12.4%since 2016
FY2026 revenue
¥453.3B▲ +13.7%
FY2026 net income
¥106.9B▲ +352.2%
FY2026 free cash flow
¥67.1B▲ +738.6%

Sumitomo Pharma income statement

Sumitomo Pharma income statement
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Revenue453,294398,832314,558
Gross profit256,893245,395187,981
Operating income107,33828,804-354,859
Pretax income100,34417,611-323,114
Net income106,86523,634-314,969

Sumitomo Pharma balance sheet

Sumitomo Pharma balance sheet
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Cash and cash equivalents44,31023,11629,047
Total assets804,571742,604907,506
Total liabilities512,104573,125751,370
Total equity292,467169,479156,136
Long-term debt179,056258,982133,367

Sumitomo Pharma cash flow statement

Sumitomo Pharma cash flow statement
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Operating cash flow71,71516,500-241,893
Capital expenditure-4,609-8,498-10,771
Free cash flow (derived)67,1068,002-252,664
Dividends paid-2-3-2,792

Half-year highlights

Half-year highlights
JPY millionsH1 FY2027H1 FY2026H1 FY2025H1 FY2024
Period ended30 Sep 202630 Sep 202530 Sep 202430 Sep 2023
Revenue266,490227,122180,749152,642
Operating income42,27696,157-8,179-86,498
Net income38,23898,860-32,229-67,741
Operating cash flow16,67318,0254,552-174,497
Total assets851,053778,404799,7651,148,855

Sumitomo Pharma major shareholders

Sumitomo Pharma major shareholders
HolderShare of classSharesFiled
SUMITOMO CHEMICAL COMPANY, LIMITED51.7%205,634,00023 April 2026

Sumitomo Pharma EDINET filings

Sumitomo Pharma EDINET filings
FiledFormType
2 November 2026Semiannual Securities ReportHalf-year report
2 September 2026Extraordinary ReportCurrent report
26 June 2026Extraordinary ReportCurrent report
23 June 2026Annual Securities ReportAnnual report
8 April 2026Extraordinary ReportCurrent report
25 March 2026Extraordinary ReportCurrent report
4 November 2025Semiannual Securities ReportHalf-year report
31 October 2025Extraordinary ReportCurrent report

Common questions

What was Sumitomo Pharma's revenue in fiscal 2026?

Sumitomo Pharma reported ¥453.3 billion in revenue for fiscal 2026, the year ended 31 March 2026, up 13.7% from fiscal 2025.

What was Sumitomo Pharma's net income in fiscal 2026?

Sumitomo Pharma reported net income of ¥106.9 billion for fiscal 2026, the year ended 31 March 2026, up 352.2% from fiscal 2025.

What was Sumitomo Pharma's free cash flow in fiscal 2026?

Sumitomo Pharma had ¥67.1 billion in free cash flow in fiscal 2026. Operating cash flow was ¥71.7 billion and capital expenditure was ¥4.6 billion.

What were Sumitomo Pharma's total assets at the end of fiscal 2026?

Sumitomo Pharma reported total assets of ¥804.6 billion at the end of fiscal 2026, the year ended 31 March 2026.

How much Sumitomo Pharma history do I get?

Every account gets the full history, annual and semiannual, with first reported values and as of dates.